New treatment hope for women with BRCA1 breast cancers

June 7, 2017, Walter and Eliza Hall Institute
Microscopic image showing cells that could be targeted with anti-PD-L1 antibodies for immunotherapy (teal) in a biopsy sample from a triple negative breast cancer tumor. Credit: E. Nolan et al., Science Translational Medicine (2017)

Researchers have found a new way to use immunotherapy, a breakthrough mode of cancer treatment which harnesses the patient's immune system, to treat an aggressive form of breast cancer.

The researchers at Melbourne's Walter and Eliza Hall Institute and Peter MacCallum Cancer Centre have shown, for the first time, that combining two immunotherapy drugs could be effective in treating triple negative breast cancers arising in women with BRCA1 mutations.

The findings suggest that of combined immunotherapy should be considered in women with these breast cancers. Immunotherapy works by boosting the body's immune cells to attack tumours and has been a 'game-changer' for treating melanoma and lung cancers.

The study, led by the Walter and Eliza Hall Institute's Dr Emma Nolan, Professor Geoff Lindeman, Dr Daniel Gray and Professor Jane Visvader, and Peter Mac's Associate Professor Sherene Loi and Associate Professor Phillip Darcy, was published today in Science Translational Medicine.

Breast affects one in eight women in Australia. Triple negative breast cancers typically account for around 15 per cent of breast cancers, affecting around 2400 women each year, but are much more common in women with BRCA1 mutations.

Professor Lindeman, also a medical oncologist at the Royal Melbourne Hospital and Peter Mac, said triple negative breast cancers were more aggressive and more likely to recur than other breast cancers.

"Triple negative breast cancers have not seen the same improvement in targeted therapies, or survival, as some other types of breast cancer," Professor Lindeman said. "Our study showed that combining anti-PD1 and anti-CTLA4 immunotherapies with chemotherapy halted the growth of BRCA1-related tumours and significantly improved survival in laboratory models."

Researchers have shown for the first time that combining two immunotherapy drugs could be effective in treating triple negative breast cancers arising in women with BRCA1 mutations. Dr. Daniel Gray, Associate Professor Sherene Loi and Professor Geoff Lindeman (L-R) from the Walter and Eliza Hall Institute and Peter MacCallum Cancer Centre led the research. Credit: Walter and Eliza Hall Institute

Some cancer cells survive by hijacking and 'switching off' immune cells that would otherwise destroy the tumours. Anti-PD1 and anti-CTLA4 immunotherapies are so-called 'immune checkpoint inhibitors' that release the brakes on critical immune cells, enabling them to attack the tumour.

Dr Gray said previous research had shown that immunotherapy was particularly effective at treating tumours that had accumulated many mutations. "BRCA1-related triple negative breast cancers have some of the most 'chaotic' genomes, and we see many immune cells accumulate in and around the tumour," Dr Gray said.

"This suggests that the can readily detect that something is awry, but they aren't able to respond properly, because they have been disabled by tumour cells. We showed that a combination of anti-PD1 and anti-CTLA4 therapies restored their ability to attack and kill triple negative breast tumour , and very effectively control tumour growth."

Associate Professor Loi, head of breast cancer clinical trials research at Peter Mac and for the Parkville precinct, said work was already underway to translate these important findings from laboratory models of breast cancer into a clinical trial for women with the disease.

"Our lab-based findings provide compelling evidence to progress to a clinical trial of this combination of immunotherapy drugs, and chemotherapy, in women with BRCA1-related breast cancer," Associate Professor Loi said. "There is also a rationale to consider the same for BRCA2-related cancers and triple negative breast cancer more broadly.

"Importantly, there are already a number of immunotherapy-based clinical trials underway in breast cancer and these two drugs - anti-PD1 and anti-CTLA4 - are in use for other cancers, so we would hope to begin a trial of this specific combination of immunotherapies in suitable in the near future."

Professor Lindeman said the study was a great example of what the Victorian Comprehensive Cancer Centre (VCCC) partners could achieve. "Our study brought together researchers with diverse expertise across several institutions, including PhD students from the University of Melbourne. We also benefited from our close collaboration with kConFab, a national consortium focused on familial cancer," he said.

Explore further: Promising findings towards targeted breast cancer therapy

More information: E. Nolan el al., "Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer," Science Translational Medicine (2017). stm.sciencemag.org/lookup/doi/ … scitranslmed.aal4922

Related Stories

Promising findings towards targeted breast cancer therapy

November 14, 2016
New research led by Conway Fellow, Professor Joe Duffy and Professor John Crown in St Vincent's University Hospital has reported for the first time on a new treatment that could be used in the majority of patients with triple ...

One in five breast cancer patients could benefit from existing treatment, genetic study reveals

March 13, 2017
Researchers from the Wellcome Trust Sanger Institute and their collaborators have discovered that a greater number of breast cancers are genetically similar to rarer cases with faulty BRCA1 or BRCA2 genes. The results published ...

New agents show promise for treating aggressive breast cancers

July 18, 2011
Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

Discovery of potential treatment for aggressive form of breast cancer

November 2, 2016
A new drug could be used to treat one of the most aggressive forms of breast cancer, a research centre based at University College Dublin and St Vincent's Hospital has discovered.

Even low-androgen triple-negative breast cancer responds to anti-androgen therapy

February 24, 2015
A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics shows that only about 1 percent of triple-negative breast cancer cells in a tumor must be "androgen-receptor-positive" ...

New anti-cancer compound shows promise for breast cancer

July 8, 2013
Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer.

Recommended for you

New drugs are improving survival times for patients with aggressive type of blood cancer, study finds

June 25, 2018
Survival times for a highly aggressive type of blood cancer have nearly doubled over the last decade due to the introduction of new targeted drugs, a Yorkshire study has shown.

Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant

June 21, 2018
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.

Existing treatment could be used for common 'untreatable' form of lung cancer

June 21, 2018
A cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available.

Novel therapy makes oxidative stress deadly to cancer

June 21, 2018
Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.

Researchers uncover new target to stop cancer growth

June 21, 2018
Researchers at the University of Wisconsin-Madison have discovered that a protein called Munc13-4 helps cancer cells secrete large numbers of exosomes—tiny, membrane-bound packages containing proteins and RNAs that stimulate ...

Higher body fat linked to lower breast cancer risk in younger women

June 21, 2018
While obesity has been shown to increase breast cancer risk in postmenopausal women, a large-scale study co-led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher found the opposite is true ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.